Expedition Therapeutics Raises $115 Million Series B As EXPD-101 Enters Phase 2 COPD Trial
Expedition Therapeutics (EXPD-101) raised an oversubscribed $115 million Series B led by General Atlantic, with RA Capital and Vivo Capital and other investors. The company dosed the first patient in a global Phase 2 COPD trial of its DPP1 inhibitor EXPD-101. Expedition said Phase 1 showed dose-proportional PK for once-daily oral dosing and no dose-limiting toxicities.
How this was made
The 30-second read
Why it matters
The combination of an oversubscribed Series B and first-patient dosing is a concrete execution and funding milestone that can shift near-term expectations for trial progress and runway.
Market read
Traders may re-rate EXPD on improved financing visibility and reduced execution risk as the company transitions from Phase 1 to Phase 2 in COPD.
What to watch
Key value driver is Phase 2 readout timing and endpoints; the article provides no efficacy data, only dosing, tolerability, and PK from Phase 1.
Background
Expedition is advancing EXPD-101, a next-generation DPP1 inhibitor, toward Phase 2 evaluation in COPD with a global randomized study design.
Ticker impact
Expedition Therapeutics raised a $115M Series B and dosed the first patient in EXPD-101’s global Phase 2 COPD trial.
Likely near-term positive bias as traders price in improved runway and trial momentum; magnitude depends on broader biotech risk appetite.
The article discloses two fresh, time-sensitive catalysts for the issuer: a newly announced oversubscribed Series B and first-patient dosing for a Phase 2 COPD study.
Market effects
Adds incremental validation for DPP1 inhibitor strategy in COPD and may support sentiment toward inflammatory-respiratory biotech programs.
Primarily US biotech sentiment; investor syndicate includes global life-science funds.
Global Phase 2 design and multinational investor participation can attract cross-border biotech capital flows.
Counterpoint
A financing headline can be partially dilutive, and first-patient dosing does not guarantee efficacy or safety outcomes in Phase 2.
Key entities
- companyExpedition Therapeutics
Raised $115M Series B and dosed the first patient in EXPD-101’s global Phase 2 COPD trial.
- drug_candidateEXPD-101
Next-generation DPP1 inhibitor being advanced for COPD; Phase 2 dosing has begun.
- investorGeneral Atlantic
Led the Series B and will add Brett Zbar to Expedition’s board.
.webp%253Fdisable%253Dupscale%2526width%253D1200%2526height%253D630%2526fit%253Dcrop&w=3840&q=75)
